Back

Time to consider atrial and diastolic function as key drivers of major adverse cardiovascular events in hypertrophic cardiomyopathy

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Comprehensive phenotyping and real-world impact in hypertrophic cardiomyopathy Hypertrophic Cardiomyopathy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Andre Martins

Leiria Hospital Centre, Leiria (Portugal)

6 More presentations in this session

Presentation thumbnail
Clinical and economic burden in NYHA class I versus II-IV hypertrophic cardiomyopathy: real-world survey data from the United States of America
Doctor P. Gebrehiwet (South San Francisco, US)
Abstract
Presentation thumbnail
Differentiating hypertrophy phenocopies from afterload-induced left ventricular hypertrophy using artificial intelligence-enabled electrocardiography
Mr D. Ahmetagic (Utrecht, NL)
Abstract
Presentation thumbnail
Patient characteristics in pediatric hypertrophic cardiomyopathy: insights from an observational study
Mrs X. Pan (Princeton, US)
Abstract
Presentation thumbnail
Impact of guideline-directed medical therapies on clinical and economic outcomes in nonobstructive hypertrophic cardiomyopathy: analysis of data from a multinational cross-sectional survey
Doctor P. Gebrehiwet (South San Francisco, US)
Abstract
Presentation thumbnail
Sex-related differences in HCM: cardiogenetics, disease severity and major outcomes
Doctor R. Esculudes Dos Santos Ferrao Gomes (Lisboa, PT)
Abstract

Access the full session

Session thumbnail
Comprehensive phenotyping and real-world impact in hypertrophic cardiomyopathy

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources